The Patent Paradox: Why India’s Startup Filing Surge is 83% Failure and All About Optics

Fragile gold patent scroll on a precarious foundation, with the number 83% failure rate overlaid, symbolizing the optical illusion of India's startup patent filing surge.

A deep dive into the intellectual property (IP) landscape of India’s booming startup sector reveals a critical gap between ambition and execution, suggesting that the much-lauded surge in patent filings is predominantly a tactical exercise in investor signalling rather than a genuine marker of technological innovation. The core issue, critics argue, is a “crisis of intent” where patents function as “decorative rather than functional” assets.   

While global bodies like the World Intellectual Property Organization (WIPO) have celebrated India’s rapid ascent—the WIPO 2024 report noted a phenomenal 15.7% growth in patent applications in 2023, positioning the country 6th globally with 64,480 filings —the internal data paints a sobering picture of weak follow-through.   

The Data Gap: 83% of Startup Patents Fail to Secure a Grant

Analysis of the startup patent pipeline from 2021 through 2025 reveals a profound drop-off rate, demonstrating that the vast majority of filings are not carried through to completion.   

During this five-year period, Indian startups filed a robust 13,089 patent applications. Yet, only 2,174 of these successfully navigated the examination process to achieve the grant stage. This results in a grant success rate of barely 16.6%, meaning approximately one out of every six startup filings becomes an enforceable, proprietary asset.   

The failure rate is compounded by active abandonment. Nearly 500 startup patent applications were explicitly withdrawn or abandoned early, often due to the filers failing to complete detailed specifications or respond to subsequent office actions required by the Patent Office.   

This pattern extends beyond patents. Startups filed 44,517 trademark applications during the same period, with over 1,300 subsequently abandoned. Analysts suggest this widespread non-prosecution across IP types confirms that the primary function of the filing is “brand optics” rather than a rigorous, long-term IP strategy. The high volume of dropped applications confirms that for many, the intent was temporary and instrumental: the patent filing was merely a transaction used to secure funding, not an investment in an enduring intellectual asset.   

Investor Mandate: Patents as Pitch Deck Tools

The distortion in filing behaviour is traced back to the venture capital (VC) ecosystem’s preference for strong valuation narratives. In competitive fundraising rounds, a pending patent application, particularly a cheap and fast provisional filing, serves as a high-visibility proxy for technological differentiation and market moat potential.   

A provisional patent application, which secures an immediate priority date, is leveraged as a “fast, affordable way to strengthen a fundraising narrative” and “create the appearance of a breakthrough innovation”. This mechanism enables a “Capital first, commitment later” ethos.   

The systemic issue is rooted in the fact that investors often prioritize the inclusion of an IP slide over demanding proof of prosecution commitment or demonstrated R&D investment. As the analysis notes, “Once the funding round closes, priorities may shift,” leading to a predictable loss of enthusiasm for the labour-intensive and expensive work required to turn provisional filings into complete specifications. This rational response by founders—underinvesting in expensive, long-term R&D in favour of cheap, high-volume filing tactics—systematically shifts resources away from core innovation.   

Structural Deficiency: India’s R&D Investment Stagnation

The crisis of intent at the startup level is underpinned by a deep, structural R&D deficit at the national level. The commitment to deep, foundational research necessary to generate truly novel and patentable inventions remains structurally low in India.   

Official data from the Department of Science & Technology (DST) confirms that India’s Gross Expenditure on Research and Development (GERD) as a percentage of GDP stood at 0.64% during the fiscal year 2020–21, having remained stagnant between 0.6% and 0.7% in the preceding years (0.66% in 2018–19 and 2019–20).   

This figure is significantly “below global average and lower than countries like China, South Korea and US”. This structural weakness is compounded by low private sector contribution, which accounted for only 36.4% of the total GERD in 2020–21, in sharp contrast to innovation-leading nations where private industry drives over 70% of R&D expenditure.   

This macro-level underinvestment directly correlates with the micro-level deficiencies, as most startups lack “dedicated research teams, technical drafting expertise, prior-art assessment systems, and time for iterative processes” necessary for rigorous patent prosecution.   

Policy Flaw: Incentives Reward Filing, Not Granting

Current government policies designed to stimulate IP activity, while successful in boosting filing volume, have inadvertently intensified the focus on volume over quality. The government successfully implemented significant fee concessions, including an 80% reduction in patent filing fees for startups, MSMEs, and educational institutions.   

However, the design flaw is that these incentives are tied to the input stage (filing) rather than the output stage (grant or commercialization). By heavily subsidizing the initial filing, the state inadvertently subsidizes the creation of the fundraising narrative for VCs. Once the provisional application is lodged, the startup has secured its priority date and the narrative benefit, but the subsequent costly work of prosecution remains unassisted, cementing the low-commitment behaviour.   

Blueprint for Genuine Innovation: Shifting from Decoration to Depth

To foster genuine innovation and correct the systemic inefficiencies, experts advocate for a strategic overhaul of incentives and infrastructure.   

  • Realign Incentives: Government benefits, including subsidies and fast-track examination provisions, must be decoupled from the act of filing and strategically tied to demonstrable outcomes, such as patent grants, successful long-term renewal, or demonstrable commercial utilization.   
  • Enhance Capacity: Urgent investment in the Patent Office is mandatory, including expansion of examiner capacity and specialized domain expertise. There is a pronounced need for more technically specialized patent officers, particularly in cutting-edge technological areas like AI, biotech, semiconductors, climate-tech, and advanced manufacturing.   
  • Strengthen R&D Culture: The government should offer targeted, co-funded grants and innovation-linked incentives for startups that demonstrate a commitment to establishing and maintaining dedicated R&D teams or formalized collaboration with research institutions.   
  • Promote Co-patenting: Actively promoting policy frameworks that encourage joint patent filings (co-patenting) between startups and premier academic/research institutions, such as the IITs and national labs, would guarantee a higher technical standard for the filings and create structured pathways for knowledge transfer.   

The conclusion remains clear: for India to genuinely transition from an IP volume leader to a global innovation power, the focus must shift from decorative filings to functional intellectual assets. Only then can “depth replace decoration” and solidify India’s reputation as a serious, quality-driven innovation hub.   

Fitterfly Patent Victory: AI-Driven PGR Tech Secures IP, Revolutionizes Diabetes Care in India

Fitterfly PGR technology patent diagram showing AI analysis of CGM data for diabetes outcomes

Digital health just scored a decisive victory. Fitterfly, the pioneering digital therapeutics arm of PB Health, secured a crucial Government of India patent. This patent protects its proprietary Personalised Glycemic Response (PGR) technology. The move cements Fitterfly’s dominant position. It dramatically alters the future of chronic disease management in India.

AI Engine Powers Precision Care

The patent covers the core of Fitterfly’s diabetes program. This AI-led engine is the PGR technology. It allows data-driven care at massive scale. PGR helps millions manage diabetes better. It predicts how specific foods and activities impact blood sugar. It makes this prediction up to three hours in advance.

This prediction power is a game-changer. It removes the daily burden of food decisions for patients. PGR moves far beyond standard, generic advice.

The model boasts a huge training dataset. It analysed over 10 lakh (1 million) Continuous Glucose Monitoring (CGM) data points. It studied over 1.21 lakh individual meals. The algorithm factors in every critical metric. These include age, BMI, heart rate, sleep, and co-morbidities. This process delivers highly accurate, personalised glucose predictions.

Clinical Outcomes Prove Efficacy

The technology already boasts unmistakable clinical success. Over 40,000 members have benefited from the PGR-powered programs. The results are clinically significant, matching high-grade pharmaceutical interventions.

In 2025, 94% of members with very high baseline HbA1c levels (above 9%) saw massive improvement. They recorded an average reduction of 2.8 points within 6 to 12 months. This outcome is comparable to standard multi-drug regimens.

Furthermore, Fitterfly’s data confirms that diabetes remission is possible. It applies to a large number of Type 2 Diabetes cases, particularly in the early stages. The program also delivers holistic health gains. Members improved critical markers. These include reduced serum cholesterol, lower triglycerides, and better blood pressure control. This success transforms patients’ quality of life. It substantially reduces future complication risks.

Dr. Vineet Nair, Head of Program Design at Fitterfly, affirmed the approach. “PGR helps us go beyond standard protocols,” he said. “It delivers care that adapts to each member’s data. This drives better adherence. It guarantees improved glucose control and more consistent progress.”

Patent Builds a Commercial Fortress

The patent acquisition is a legal triumph. It gives Fitterfly a formidable fortress of Intellectual Property (IP).

The Government of India approval confirms the unique nature of the PGR algorithm. It grants Fitterfly exclusive commercial rights. This protection shields the company from direct competition. It also exponentially increases PB Health’s valuation. The technology shifts from a service model to a protected, scalable asset.

Dr. Arbinder Singal, Head of Preventive and Digital Health at PB Health and Co-founder at Fitterfly, emphasized the strategic importance. “Our proven outcomes and proprietary technology add significant value,” he stated. “The patent secures the technical core of our chronic disease management offering.”

The move reinforces PB Health’s vision. They aim to create a tech-first, integrated healthcare ecosystem. Fitterfly’s digital expertise becomes the crucial preventative arm. This balances PB Health’s growing hospital network in the Delhi-NCR region.

India’s Health System Faces Transformation

Chronic conditions devastate India’s population. Nearly 40 percent of Indian adults suffer from diabetes, hypertension, or obesity. This is an immense, growing crisis.

Technology like PGR offers the only viable path to scale positive change. It empowers patients, doctors, and insurers alike.

For Insurers: Diabetes remains the biggest cost driver. Fitterfly’s outcome-led programs offer a clear solution. They reduce the risk of progression and expensive hospitalizations. Several leading insurance companies already recognize this shift. They integrate Fitterfly’s programs into their policyholder ecosystem. This acts as a proactive risk management measure. It lowers long-term claims.

For Patients: PGR grants control. It is a fundamental shift from reactive treatment. It establishes continuous, outcome-led management. This approach improves long-term disease stability. It leads to huge cost savings and boosts work productivity.

Dr. Singal added, “We are working closely with leading insurers. We are shifting the focus from treatment to long-term health stability. This is a crucial step. It builds a more sustainable, future-ready healthcare model for India.”

The successful patenting of PGR technology marks a definitive moment. It confirms that Digital Therapeutics (DTx) is not a supplement. DTx is becoming the first line of defence against India’s escalating chronic disease epidemic. This victory is a resounding signal. Personalised, AI-driven healthcare is now locked in. It is set to dominate the market.